Interim report
Q3 2024

alzinova

We will make it possible for Alzheimer's patients to live an *independent and active life.*

Highlights during the period

Tord Labuda new CEO from October 1st

Tord Labuda is appointed new CEO of the company from 1 October 2024.

First patient has completed the phase 1b study

The first participant completed the entire phase 1b study with ALZ-101.

All patients dosed in part A2

All patients in the high dose part of the phase 1b study with ALZ-101 have received their last dose.

Key figures from the period

THREE MONTHS, JULY–SEPTEMBER, 2024

- Net sales amounted to SEK 0 thousand (0).
- Loss after financial items amounted to SEK -4,151 thousand (-3,549).
- Average number of shares during the period amounted to 88,462,793 (44,531,265).
- Earnings per share amounted to SEK -0.05 (-0.08).

NINE MONTHS, JANUARY–SEPTEMBER, 2024

- Net sales amounted to SEK 30 thousand (0).
- Loss after financial items amounted to SEK -13,990 thousand (-11,749).
- Average number of shares during the period amounted to 59,281,997 (38,985,372).
- Earnings per share amounted to SEK -0.24 (-0.30).

There are no dilution effects regarding the number of shares.
Amounts in brackets: Corresponding period in previous year.
"the Company" or "Alzinova" refers to Alzinova AB with corporate identity number: 556861-8168.

Significant events during the third quarter 2024

- All patients in part A2 of the phase 1b study had received the first dose of ALZ-101 by July.
- The Board of Directors decided to appoint Board member Carol Routledge as acting CEO of Alzinova from August 1, 2024, until a permanent CEO is recruited.
- Alzinova published further details of the data presented in a poster presentation at AAIC in July 2024.
- Alzinova updated the market that the Company has accelerated the partnering process. Among other things the Company has engaged with a renowned US Adviser, covering life sciences consulting, M&A and investment banking, to assist the company in identifying and subsequently signing a partner agreement.
- In August, the Company updated the market on the status of the various parts of Alzinova's phase 1b study.
- In September, the first study participant had successfully completed the entire phase 1b study with ALZ-101.
- The Board appointed Tord Labuda as the new CEO of Alzinova, effective 1 October 2024.

Significant events after the end of the third quarter 2024

- All patients in the high dose part (part A2) of the phase 1b study have received their last dose.
- Alzinova announced that patient data from the extension part of the phase 1b study with ALZ-101 is being processed. Results are expected around the end of November-December 2024.

A word from CEO Tord Labuda

A new era for Alzinova

Dear shareholder,

It is with great enthusiasm and humbleness that I have taken on the role as the new CEO of Alzinova AB. Having taken office on 1 October, I now have the exciting task of leading this innovative company into the next phase of our clinical development and growth.

Our unique position in Alzheimer's research

Alzinova is a pioneer in the development of treatments for Alzheimer's disease, and I am deeply impressed by the strong scientific foundation laid by my predecessors and our entire dedicated team. Our unique approach focusing on an amyloid-beta oligomer-specific immunotherapy positions us as a pioneer in Alzheimer's research, and the progress we have made so far, both preclinically and in the first patient studies, is very promising for our further journey.

Insights and potential

During my first six weeks, I have spent a lot of time understanding our ongoing projects and listening to our employees, partners and shareholders. It is clear that we have significant potential to build on, especially considering the results from our phase 1b study with ALZ-101, which targets the neurotoxic amyloid-beta oligomers, as well as with ALZ-201, our antibody therapy against the same toxic oligomers, currently in the preclinical phase.

Key milestones ahead

Our main priority going forward will be to accelerate our clinical development programme and we are looking at some key milestones in the next six months:

• In Q4, we expect to present long-term data (up to week 42) from the extension part (part B) of our phase 1b study, i.e. patients have been in the phase 1b study for at least 84 weeks. Provided that these data are in line with our analysis earlier in the year, from part A1 where we saw good safety and tolerability, a dose-dependent immune response and excellent biomarker data, we will be able to strengthen our position in the ongoing discussions for further funding and potential partnerships.

• Recently, the last patient in the high dose part, A2 of the phase 1b-study, was dosed, where patients received 400ug in 4 doses over 16 weeks. This will be followed by a 4-week follow-up and we expect to report data early in the new year. The focus here is safety, tolerability and immune response, which will give us valuable insight for future phase 2 studies.

• Looking ahead, we are working intensively on the important preparatory steps for a phase 2 study including protocol development, manufacturing of study drugs and selection of a contract research organisation (CRO). This work is crucial to ensure a smooth transition to the next phase of our clinical programme and thereby maximise the chances of success.

”Alzinova is a pioneer in the development of treatments for Alzheimer’s disease”

Financial strength and outlook
Financially, we have strengthened our position through the successful rights issue earlier this year, giving us the resources to drive our clinical development forward in the near term. However, we recognise that the continued development of ALZ-101 will require significant investment. As we approach phase 2, we are of course carefully evaluating different options - from strategic partnerships that can provide both financial resources and expertise to more traditional capital raising that can enable us to run the phase 2 study on our own - to ensure that we have the resources needed to realise the full potential of our pipeline. Our goal is to make the best informed decisions to position Alzinova for success in the challenging but promising world of Alzheimer’s research.

Our results so far have attracted significant industry interest and we look forward with confidence to the world’s largest pharmaceutical conference, JP Morgan, in January. There, with new clinical data, we will hopefully be in a stronger position to continue our discussions with the major pharmaceutical companies. This conference represents an important opportunity for us to present our results from the phase 1b study with ALZ-101 to potential partners and investors.

ALZ-101: A potential game-changer
Financial strength is crucial for us to fully develop our main asset - the vaccine candidate ALZ-101. With its unique mechanism of specifically targeting the toxic oligomers of amyloid-beta, ALZ-101 has the potential to be a game-changer in Alzheimer’s treatment. Positive results from our ongoing studies could open up entirely new opportunities for the company and millions of patients worldwide.

Lastly, I would like to thank you for the warm welcome I have received from the entire Alzinova family. I look forward to working with our fantastic team to take Alzinova to new heights. We have an exciting journey ahead of us, and I am convinced that with our innovation, commitment and expertise, we will continue to deliver value to our employees, shareholders and not least to our Alzheimer’s patients and their families.

Thank you for your confidence,
Tord Labuda
CEO Alzinova AB

Investment highlights

Vaccine with potential to treat Alzheimer's

Alzinova's lead candidate, ALZ-101, is a therapeutic vaccine to treat Alzheimer's disease. Positive results from part A1 of the ongoing study demonstrate good safety and tolerability and a clear immunological response.

Supplementary treatment with antibody

Based on the same technology, Alzinova is also developing a monoclonal antibody, ALZ-201, as a complementary treatment to the vaccine to combat Alzheimer's disease.

Best-in-class potential with favourable safety profile

Data show that the unique specificity of Alzinova's vaccine (ALZ-101) and monoclonal antibody (ALZ-201) provides "best-in-class" potential with a more favourable side effect profile compared to other treatments.

Regulatory progress boost collaborations

Positive feedback from the FDA and EMA as well as other ongoing activities for the next clinical development phase, together with strong IP, make Alzinova's candidates attractive for strategic partnerships.

Enables an independent and active life

About Alzinova

Alzinova AB is a Swedish biopharmaceutical Company specializing in the treatment of Alzheimer's disease. The Company's patented AβCC peptide technology™ enables the development of disease-modifying therapies with the potential to selectively neutralize the toxic accumulations of the amyloid beta peptide, so-called oligomers, which are central to the onset and progression of Alzheimer's disease.

With this technology, we can develop effective treatments that have a favorable profile with a lower risk of side effects compared to other treatments. Promising preclinical results have been obtained following a study on brain extracts from deceased Alzheimer's patients, demonstrating evidence of the mechanism of these actions.

Alzinova's primary focus is the development of a vaccine that is being developed as a long-acting treatment for Alzheimer's disease. The vaccine candidate ALZ-101 is in clinical development with a phase 1b study in Alzheimer's patients started Q3 2021. Based on positive interim data from part A1, the Company has initiated an extension part, part B, of the study, which is expected to be completed in early 2025.

Part A1 of the study was completed at the end of 2023 with positive results, showing ALZ-101 to be both safe and well tolerated. In addition, a clear immunological response was noted as well as a response in biomarkers associated with Alzheimer's disease. The results from the complete analysis of part A1 open up the possibility of evaluating a further, higher dose. Alzinova has therefore initiated dosing an additional cohort with 400 µg of ALZ-101, which was implemented in 2024. Overall, the results of preclinical and clinical studies mean that Alzinova has the potential to develop a treatment that is differentiated from other treatments currently on the market.

Based on the same AβCC peptide technology, the Company is also developing the ALZ-201 antibody, which is currently in preclinical development. The project portfolio for the development of disease-modifying treatments is being broadened as the Company prepares the antibody for clinical development. Alzinova was founded by researchers who have worked at the MIVAC research center at the University of Gothenburg, and by GU Ventures AB.

Alzheimer's disease

In Alzheimer's disease, the nerve cells in the brain are damaged by abnormal protein deposits that mainly consist of amyloid-beta 42 (Aβ42), a type of small protein that also occurs in a healthy brain. When the Aβ42 molecule clumps together, stable accumulations are formed in the brain, plaques, but also so-called oligomers.

Oligomers differ structurally from the plaque and, unlike the plaque, are highly toxic to brain cells. They damage important functions that make the contact surfaces between the nerve cells, the synapses, stop working normally. Synapses are the places in the brain where electrical and chemical signals are transmitted from one nerve cell to another, and their function is critical to our ability to remember, react, think and act. Eventually, due to synaptic impairment, the nerve cell dies.

The disease first affects the parts of the brain that handle short-term memory, but eventually the disease spreads over the entire brain and the patient finds it increasingly difficult to carry out daily tasks. In the end, the patient cannot manage on their own, but requires care and continuous monitoring.

Alzheimer's is a disease that basically anyone can get, and which is strongly age-dependent. Over 95% of all cases affect those over the age of 65, and in these cases there is not a strong genetic component driving the disease.

Alzheimer's is most common in the elderly population, with 1 in 9 people over 65 affected, 65% of whom are women. However, about 5% of cases are diagnosed at an earlier age.



Business model

Alzinova's business model is to drive projects into clinical development with the aim of documenting that the drug candidates are safe and well tolerated as well as demonstrating proof-of-concept, i.e. that they exhibit efficacy in patients with Alzheimer's disease. Based on positive clinical data, the Company has identified several potential strategic partners who have the resources and in-house expertise to conduct the studies needed for registration and commercialisation. This can be done through out-licensing with a partnership where the Company jointly brings the drug to the market with the collaboration partner, or by selling the drug candidate for further development.

Out-licensing

A common alternative for development companies like Alzinova is to out-license projects to one or more pharmaceutical companies. Either these can get exclusivity in a limited market, and you agree with several partners to cover the market globally, or you have a global partner who takes the drug to the entire market. A typical arrangement for out-licensing is initial compensation and then future installments linked to pre-defined milestones during further development, the regulatory process and commercialization with high revenues linked to future drug sales.

The Company has so far taken several important steps towards out-licensing and commercialization. The data shows "best-in-class" potential, which is very attractive for partnering. With positive results in the Company's two drug projects, ALZ-101 and ALZ-201, there are several options. One is to out-license the ALZ-101 vaccine to a major pharmaceutical company, and another option is for Alzinova to take ALZ-101 through phase 2 and then out-license it to a partner. For the antibody ALZ-201, this could be out-licensed immediately during the preclinical phase, or alternatively after phase 1b studies. The Company's focus going forward is on business development with several ongoing dialogues in parallel with clinical development of the project portfolio.

Market

Every year around 10 million people in the world become ill with some form of dementia, of which Alzheimer's disease accounts for around 60-70 %. Today, it is estimated that there are approximately 55 million patients with dementia in the world, but it is difficult to diagnose dementia today at early stages of disease. Therefore, it is expected that this figure is significantly higher. In addition, this number is expected to increase to more than 130 million by 2050. It is estimated that more than 30 million people in the world today have Alzheimer's disease and the number is expected to triple by 2050[1].

The societal costs of dementia diseases are currently estimated at $1,300 billion annually[2]. The drug cost of Alzheimer's medications, which are symptom relief alone, amounts to approximately $6 billion annually. While the first disease-modifying drugs has recently been approved in the United States, Japan and China there is still a very long way to go to truly treat and prevent the progression of Alzheimer's disease.

The sales and revenue potential of a new effective disease-modifying drug is therefore significant even if it would only have an initially limited market share. By 2026, drugs for Alzheimer's disease are expected to be represented among 2 out of 7 expected top sellers (pharmaceutical companies), with an expected annual turnover of USD 1.7-4.5 billion[3]. The reason why the initial sales estimates are relatively low is that there have been no good medical alternatives. With effective treatment options coming to the market, such as Alzinova's drug, the Company estimates that annual sales can be multiplied several times compared to today.

The research firm Global Data estimates that annual sales for disease-modifying drugs for Alzheimer's disease will reach roughly $13 billion by 2028 in the largest markets: the United States, Germany, France, the United Kingdom, Italy, Spain, Japan, China, and India. An approved disease-modifying treatment for Alzheimer's disease has the potential to generate peak annual sales in excess of USD 10 billion[4].

1) World Health Organization (WHO) – Facts about Dementia, March 2023
2) World Alzheimer's Report, 2024.
3) Drugs to watch report, 2022.
4) US, Germany, France, UK, Italy, Spain, Japan, China. GlobalData, Pharma, June 7, 2023.

Alzinova's competitive advantages



Based on statistics from Statistics Sweden (SCB) about the Swedish healthcare system, and that the two treatments have equivalent clinical efficacy, total treatment duration and drug cost.

Alzinova is developing a vaccine candidate to treat Alzheimer's disease. The vaccine, unlike other treatments such as antibodies, is expected to require only a few doses a year rather than as often as every two weeks. In addition, it can be given to patients in a very time-efficient way through a simple injection in primary care or at home by a nurse. Other treatments are time-consuming and require hospital care.

To treat patients with therapeutic antibodies, this sharply increases societal costs, resulting in fewer patients being treated with an antibody treatment. With Alzinova's vaccine, compared to antibody treatment, healthcare and societal costs can be reduced, which creates the opportunity for more people to receive treatment.

Financial information

Corporate structure and shareholding
Alzinova has no subsidiaries and is not part of any group. Neither does the Company hold any shares.

Financial development
During the period July - September, the Company has continued to invest in the further development of ALZ-101, which is in the final phase of the phase 1b study, where an open-label extension part and a high-dose part are ongoing. The Company is also continuing to invest in preparations for clinical phase 2 and in preparations for clinical studies of the ALZ-201 antibody.

The Company's total costs during the third quarter of 2024 amounted to SEK 9,840 (6,829) thousand. Of the period's costs, SEK 5,771 (3,300) thousand relates to research and development (R&D) costs, including costs for the ongoing clinical study (including the extension and high-dose parts), as well as preparations for the production of drug substance for the start of the upcoming phase 2 clinical study. The Company's R&D costs have been capitalised in the balance sheet. Of the total costs, personnel costs during the period amounted to SEK 2,682 (2,204) thousand.

Cash flow from operating activities during the third quarter amounted to SEK 22,688 (-3,675) thousand. Cash flow from investing activities consists of expenditure for ongoing capitalised R&D costs and amounted to SEK -5,771 (-3,300) thousand during the same period. Cash flow from financing activities amounted to SEK 30,517 (0)thousand and stems from the oversubscribed rights issue registered in the third quarter.

Financial position
At the end of the period, the Company's equity totalled approximately SEK 130,386 (118,589) thousand with an equity ratio of 93.1% (93.9%), and total cash holdings amounted to approximately SEK 22,674 (32,905) thousand.

As there is ongoing work on various strategic financing options. In order to further strengthen the Company's position and to secure liquidity in the short term and the requirement for working capital, the Company has received a binding promise of temporary financing on market terms through Maida Vale Capital AB, which is the Company's single largest shareholder.

Rights issue
During the quarter, the Company completed an oversubscribed rights issue, which provided the Company with a total of SEK 30.5 million after deduction of issue costs. The number of shares in Alzinova then amounts to 89,165,460 shares, with a total share capital of SEK 21,750,341. For shareholders who did not participate in the rights issue, the dilution amounted to approximately 50% based on the total number of shares in the Company.

Risk factors
A detailed assessment of the Company's uncertainty factors was included in the Annual Report 2023 and in the prospectus published in connection with the rights issue in June 2024.

Auditor's review
This report has not been reviewed by the Company's auditors.

Policies for the preparation of the interim financial report
The interim financial report is prepared in accordance with the Swedish Annual Accounts Act as well as the Swedish Accounting Standards Board BFNAR 2012:1 annual report and consolidated (K3).

The Board of Directors and the Chief Executive Officer hereby confirm that this interim report provides a true and fair view of the Company's operations, financial position and earnings, and describes significant risks and uncertain factors the Company is facing.

Mölndal, November 14, 2024
Alzinova AB (publ)

Income statement

(TSEK)	2024-07-01 2024-09-30 3 months	2023-07-01 2023-09-30 3 months	2024-01-01 2024-09-30 9 months	2023-01-01 2023-09-30 9 months	2023-01-01 2023-12-31 12 months
Net sales	-	-	30	-	270
Own work capitalized	5,771	3,300	11,479	13,990	19,604
	5,771	3,300	11,509	13,990	19,874
Operating expenses					
Other external expenses	-7,159	-4,625	-17,728	-19,506	-27,097
Personnel expenses	-2,682	-2,204	-7,581	-6,193	-9,299
Operating result	**-4,069**	**-3,529**	**-13,801**	**-11,709**	**-16,522**
Result from financial items					
Interest income	1	0	1	1	140
Interest expenses	-83	-20	-190	-41	-98
Result after financial items	**-4,151**	**-3,549**	**-13,990**	**-11,749**	**-16,480**
Result before tax	**-4,151**	**-3,549**	**-13,990**	**-11,749**	**-16,480**
Result for the period	**-4,151**	**-3,549**	**-13,990**	**-11,749**	**-16,480**

Balance sheet

(TSEK)	30 Sep 2024	30 Sep 2023	31 Dec 2023
ASSETS			
Fixed assets			
Intangible assets			
Capitalized expenditure for development work	107,732	90,639	96,253
Patent	1,632	1,632	1,632
	109,364	**92,271**	**97,885**
Total fixed assets	**109,364**	**92,271**	**97,885**
Current assets			
Short term receivables			
Tax receivables	235	223	257
Other receivables	288	594	378
Prepaid expenses and accrued income	2,477	335	2,643
	3,001	**1,152**	**3,278**
Cash and cash receivables	**27,674**	**32,905**	**22,026**
Total current assets	**30,675**	**34,057**	**25,304**
TOTAL ASSETS	**140,039**	**126,328**	**123,189**
EQUITY AND LIABILITIES			
Equity			
Restricted equity			
Share capital	21,750	11,712	11,712
Fund for development costs	105,668	88,576	94,190
	127,418	**100,288**	**105,902**
Unrestricted equity			
Share premium	186,743	166,264	166,264
Retained result	-169,786	-136,214	-141,828
Result for the year/period	-13,990	-11,749	-16,480
	2,967	**18,301**	**7,956**
Total equity	**130,385**	**118,589**	**113,858**
Long term liabilities			
Other long term liabilities	800	800	800
	800	**800**	**800**
Current liabilities			
Accounts payable	3,918	2,015	2,493
Other current liabilities	3,326	3,260	3,413
Accrued expenses and prepaid income	1,610	1,664	2,625
	8,854	**6,939**	**8,531**
TOTAL EQUITY AND LIABILITIES	**140,039**	**126,328**	**123,189**

Change in equity, condensed

(TSEK)

Jan - Sep 2024 9 months	*Share capital*	*Fund for development costs*	*Share premium*	*Retained result incl. result for the year*	*Total equity*
At the beginning of the period	**11,712**	**94,190**	**166,264**	**-158,308**	**113,858**
Share issue	10,039	-	26,470	-	36,509
Transaction costs, share issue	-	-	-5,991	-	-5,991
Transfer within equity	-	11,478	-	-11,478	0
Net result for the period	-	-	-	-13,990	-13,990
At the end of the period	**21,750**	**105,668**	**186,743**	**-183,776**	**130,386**

(TSEK)

Jan - Sep 2023 9 months	*Share capital*	*Fund for development costs*	*Share premium*	*Retained result incl. result for the year*	*Total equity*
At the beginning of the period	**8,526**	**74,586**	**144,645**	**-122,224**	**105,533**
Share issue	3,186	-	23,098	-	26,284
Transaction costs share issue	-	-	-1,479	-	-1,479
Transfer within equity	-	13,990	-	-13,990	0
Net result for the period	-	-	-	-11,749	-11,749
At the end of the period	**11,712**	**88,576**	**166,264**	**-147,963**	**118,589**

(TSEK)

Jan - Dec 2023 12 months	*Share capital*	*Fund for development costs*	*Share premium*	*Retained result incl. result for the year*	*Total equity*
At the beginning of the period	**8,526**	**74,586**	**144,645**	**-122,224**	**105,533**
Share issue	3,186	-	23,098	-	26,284
Transaction costs share issue	-	-	-1,479	-	-1,479
Transfer within equity	-	19,604	-	-19,604	0
Net result for the period	-	-	-	-16,480	-16,480
At the end of the period	**11,712**	**94,190**	**166,264**	**-158,308**	**113,858**

Cash flow statement, condensed

(TSEK)	2024-07-01 2024-09-30 3 months	2023-07-01 2023-09-30 3 months	2024-01-01 2024-09-30 9 months	2023-01-01 2023-09-30 9 months	2023-01-01 2023-12-31 12 months
OPERATING ACTIVITIES					
Result after financial items	-4,151	-3,549	-13,990	-11,749	-16,480
Cash flow from operating activities before change in working capital	**-4,151**	**-3,549**	**-13,990**	**-11,749**	**-16,480**
Cash flow from change in working capital					
Increase (-)/Decrease (+) in operating receivables	818	35	277	150	-1,976
Increase (+)/Decrease (-) in operating liabilities	1,275	3,139	323	1,651	3,243
Cash flow from operating activities	**-2,059**	**-375**	**-13,390**	**-9,948**	**-15,213**
Investing activities					
Acquisition of intangible fixed assets	-5,771	-3,300	-11,479	-13,990	-19,604
Cash flow from investing activities	**-5,771**	**-3,300**	**-11,479**	**-13,990**	**-19,604**
Financing activities					
Share issue	36,509	0	36,509	26,284	26,284
Transaction costs share issue	-5,991	0	-5,991	-1,479	-1,479
Cash flow from financing activities	**30,517**	**0**	**30,517**	**24,805**	**24,805**
Cash flow for the period	**22,688**	**-3,675**	**5,649**	**867**	**-10,012**
Cash and cash equivalents at the beginning of the period	**4,987**	**36,580**	**22,026**	**32,038**	**32,038**
Cash and cash equivalents at the end of the period	**27,674**	**32,905**	**27,674**	**32,905**	**22,026**

The share

Alzinova's share was listed on the Spotlight Stock Market (formerly Aktietorget) on November 25, 2015. As of March 11, 2019, the Company is listed on the Nasdaq First North Growth Market in Stockholm. There is one class of shares in the Company. The share entitles to one (1) vote per share. Each share carries an equal right to a share in the Company's assets and results. As of 30 September 2024, the number of shares in Alzinova amounted to 89,165,460 (44,531,265 as of 30 September 2023).

Largest owners per September 30, 2024

Owner	*Number of shares*	*Capital %*
Försäkrings AB Avanza Pension	15,260,694	17.12%
Maida Vale Capital AB	14,632,418	16.41%
Nordnet Pensionsförsäkring AB	3,377,009	3.79%
Futur Pension	2,851,517	3.20%
Hunter Capital	2,222,222	2.49%
Patrik Ahlvin	1,885,251	2.11%
Özlem Erdogdu Gül	1,368,820	1.54%
Ålandsbanken	1,151,486	1.29%
Moll Invest AB	1,114,430	1.25%
Sara Gjertz	1,100,000	1.23%
Total 10 largest shareholders	**44,963,847**	**50.43%**
Total other shareholders	44,201,613	49.57%
Total all shareholders	**89,165,460**	**100.00%**

Stock exchange	Ticker	Listed since
Nasdaq First North Growth Market	*ALZ*	*2015*

Currently there are no long-term share-based incentive programs in the Company. There are no dilution effects regarding the number of shares.

Financial calendar

Year-end report, 2024	27 February 2024

Financial reports are available on the Company's website www.alzinova.com as of the date of publication.

Contact

Tord Labuda, CEO
tord.labuda@alzinova.com, +46 70 838 23 23

Erik Kullgren, interim CFO,
erik.kullgren@alzinova.com, +46 707 439 516

or mail directly to info@alzinova.com

Glossary, definitions and abbreviations

Aβ42 - amyloid-beta 42	A peptide (part of a protein) produced by the body that can aggregate in the brain and cause Alzheimer's disease
"Best-in-class"	A product that is considered superior to other competitors in its class, can be compared to 'first-in-class', which refers to being first to market with a product
Biomarker	A measurable indicator of a state of disease
Clinical studies	A study evaluating a medicine, conducted in humans
Disease-modifying treatment	Treatment that targets the underlying cause of the disease
EMA	European Medicines Agency
FDA	The United States Food and Drug Administration
R&D	Abbreviation for research and development
IP	Intellectual properties, for example patents
Monoclonal antibody	A type of antibody produced by a single clone of cells
Oligomers	Proteins or peptides, clumped together, used to designate soluble peptide clumps
Peptide	Part of a protein (a small chain of amino acids too small to be classified)
Plaque	Local accumulation of clumped insoluble protein, in Alzheimer's mainly consisting of the peptide Abeta42
Tolerability	The degree of side effects from a medicine that can be tolerated by a patient

Alzinova AB (publ)

Alzinova AB is a Swedish clinical-stage biopharma Company specializing in the treatment of Alzheimer's disease, which focuses on targeting toxic amyloid-beta oligomers. The lead candidate, ALZ-101, is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide™ technology makes it possible to develop disease-modifying treatments that accurately target the toxic amyloid-beta oligomers that are central to the onset and progression of the disease. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases. It is estimated that more than 30 million people in the world today have Alzheimer's disease and the number is expected to triple by 2050. Based on the same technology, the Company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The Company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com

Alzinova AB
Visiting address: Entreprenörsstråket 10, SE-431 53 Mölndal, Sweden
Postal address: Gemenskapens gata 9, SE-431 53 Mölndal, Sweden

alzinova